Ciphergen Announces Issuance of Patent for Multi-marker Diagnostics Using SELDI ProteinChip(R) Technology
May 18 2005 - 10:00AM
PR Newswire (US)
Ciphergen Announces Issuance of Patent for Multi-marker Diagnostics
Using SELDI ProteinChip(R) Technology Complements Existing Patents
Covering Ciphergen's Pattern Track(TM) Biomarker Discovery to Assay
Process FREMONT, Calif., May 18 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) announced today that it has been
granted U.S. Patent 6,844,165, directed to the detection of
multiple diagnostic markers by SELDI-TOF-MS for the diagnosis of
disease. Multi-marker assays using Ciphergen's patented SELDI
ProteinChip(R) System are the basis for the clinical diagnostic
tests that Ciphergen Diagnostics is currently developing for
commercialization. Ciphergen has several issued United States
patents that cover aspects of our integrated Pattern Track(TM)
biomarker discovery, validation and assay process. These include
U.S. patent 5,719,060, which covers the basic SELDI process; U.S.
patents 6,225,047 and 6,579,719, which cover biomarker discovery
through protein profile difference mapping using SELDI; U.S. patent
6,675,104, which covers pattern proteomics based discovery,
validation and classification of biomarker combinations
(multi-markers) using a multivariate pattern recognition algorithm;
and this new patent (6,844,165), which covers multi-marker
diagnostic assays performed on the SELDI platform. "We believe
combinations of specific, identified protein biomarkers can provide
greater predictive diagnostic value than a single biomarker," said
William E. Rich, President and CEO of Ciphergen. "Ciphergen's
family of ProteinChip technology patents form a powerful portfolio
supporting our leadership position in biomarker proteomics,
enabling Ciphergen to continue as the premier innovator in
translating pattern-based biomarker discovery to multi-marker-based
diagnostics through our Pattern Track(TM) process." About Ciphergen
Ciphergen's Diagnostics Division is dedicated to the discovery of
protein biomarkers and panels of biomarkers and their development
into protein molecular diagnostic tests that improve patient care;
and to providing collaborative R&D services through its
Biomarker Discovery Centers(R) for biomarker discovery for new
diagnostic tests as well as pharmacoproteomic services for improved
drug toxicology, efficacy and theranostic assays. Ciphergen's
Biosystems Division develops, manufactures and markets a family of
ProteinChip(R) Systems and services for clinical, research, and
process proteomics applications. ProteinChip Systems enable protein
discovery, characterization, identification and assay development
to provide researchers with predictive, multi-marker assay
capabilities and a better understanding of biological function at
the protein level. Additional information about Ciphergen can be
found at http://www.ciphergen.com/. Safe Harbor Statement Note
Regarding Forward-Looking Statements: For purposes of the Private
Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
forward-looking statements include statements regarding the
diagnostic tests that Ciphergen Diagnostics is developing, the
predictive diagnostic value of protein biomarkers, possible
improvements to assay performance through SELDI-based assays, and
the expectation that protein multi-marker tests will improve
patient care. Actual results may differ materially from those
projected in such forward-looking statements due to various
factors, including ProteinChip technology's ability to successfully
discover, validate and assay biomarkers and patterns of biomarkers
that are highly predictive and therefore meet with customer
acceptance, and our ability to protect and promote our proprietary
technologies. Investors should consult Ciphergen's filings with the
Securities and Exchange Commission, including its Form 10-Q dated
May 10, 2005, for further information regarding these and other
risks of the Company's business. DATASOURCE: Ciphergen Biosystems,
Inc. CONTACT: Sue Carruthers of Ciphergen Biosystems, Inc.,
+1-510-505-2233 Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024